Many documents listed on this page are PDF files that may be viewed using AdobeReader.

MedImmune, Inc. v. Genentech, Inc.

Subject:

Justiciability, Patents, Intellectual Property, Declaratory Judgment Act

Does Article III's grant of jurisdiction of "all Cases . . . arising under . . . the Laws of the United States," implemented in the "actual controversy" requirement of the Declaratory Judgment Act, 28 U.S.C. section 2201(a), require a patent licensee to refuse to pay royalties and commit material breach of the license agreement before suing to declare the patent invalid, unenforceable or not infringed?

• U.S. Court of Appeals - Federal Circuit Opinion Filed: October 18, 2005
• United States Supreme Court, Cert. Granted: February 21, 2006
• United States Supreme Court, Decided: January 9, 2007

Resources:

• Docket Sheet From the U.S. Supreme Court.
• Northwestern University - Medill School of Journalism: On the Docket

Briefs:     Parties Petition Phase Certiorari Petition Opposition to Petition Reply to Opposition Merits Phase Petitioner MedImmune Respondent Genentech Respondent City of Hope Amici Supporting Petitioner Amicus NRDC Amicus Solicitor General Amici Law Professors Amicus Generic Pharm. Ass'n Amicus Medtronic Amici Supporting Neither Party Amicus Licensing Executives Society Amici Supporting Respondent Amicus Pharm. Research & Manuf. of Am. Amici Licensing Experts Amici Law Professors Amici Law Professors Amici Qualcomm et al. Amici Universities Amicus AIPLA Amici 3M, et al. Amicus BPLA Amicus NYIPLA

Counsel of Record For Petitioner MedImmune, Inc.: Harvey Kurzweil Dewey Ballantine, LLP New York, NY For Respondent Genentech, Inc.: Daniel M. Wall Latham & Watkins LLP San Francisco, CA

Oct | Nov | Dec | Jan | Feb | Mar | Apr | Unscheduled | Previous Terms   To view PDF files listed on this page you will need Adobe Acrobat Reader